Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a late-stage neuropsychiatry company, announced it will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The call will offer investors and stakeholders insight into the company's progress, particularly its lead programs targeting major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Cybin is advancing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of MDD. The drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), reflecting its potential to address a significant unmet need. Additionally, CYB004, a deuterated N,N-dimethyltryptamine molecule, is in a Phase 2 study for GAD. The company also maintains a research pipeline of investigational 5-HT-receptor-focused compounds. These developments underscore Cybin's commitment to revolutionizing mental healthcare through innovative next-generation treatments.
The upcoming call comes as the mental health treatment landscape evolves, with psychedelic-assisted therapies gaining regulatory traction. Cybin's focus on deuterated compounds aims to improve efficacy and tolerability compared to existing treatments. Investors will look for updates on trial enrollment, data milestones, and financial runway. The company, founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. For more details on the press release, visit https://ibn.fm/BqH38. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.
